HALO vs. EXEL, RLAY, NVAX, ALLO, FATE, ADPT, RGEN, KOD, NBIX, and CRSP
Should you be buying Halozyme Therapeutics stock or one of its competitors? The main competitors of Halozyme Therapeutics include Exelixis (EXEL), Relay Therapeutics (RLAY), Novavax (NVAX), Allogene Therapeutics (ALLO), Fate Therapeutics (FATE), Adaptive Biotechnologies (ADPT), Repligen (RGEN), Kodiak Sciences (KOD), Neurocrine Biosciences (NBIX), and CRISPR Therapeutics (CRSP). These companies are all part of the "biological products, except diagnostic" industry.
Halozyme Therapeutics (NASDAQ:HALO) and Exelixis (NASDAQ:EXEL) are both mid-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, community ranking, institutional ownership, media sentiment, valuation, risk, earnings, analyst recommendations and profitability.
Halozyme Therapeutics has higher earnings, but lower revenue than Exelixis. Halozyme Therapeutics is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.
In the previous week, Halozyme Therapeutics and Halozyme Therapeutics both had 16 articles in the media. Halozyme Therapeutics' average media sentiment score of 0.82 beat Exelixis' score of 0.73 indicating that Halozyme Therapeutics is being referred to more favorably in the media.
Exelixis received 75 more outperform votes than Halozyme Therapeutics when rated by MarketBeat users. However, 69.02% of users gave Halozyme Therapeutics an outperform vote while only 68.09% of users gave Exelixis an outperform vote.
Halozyme Therapeutics presently has a consensus target price of $53.29, indicating a potential upside of 38.15%. Exelixis has a consensus target price of $26.29, indicating a potential upside of 10.91%. Given Halozyme Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Halozyme Therapeutics is more favorable than Exelixis.
97.8% of Halozyme Therapeutics shares are owned by institutional investors. Comparatively, 85.3% of Exelixis shares are owned by institutional investors. 2.7% of Halozyme Therapeutics shares are owned by company insiders. Comparatively, 2.9% of Exelixis shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Halozyme Therapeutics has a net margin of 33.96% compared to Exelixis' net margin of 11.35%. Halozyme Therapeutics' return on equity of 248.20% beat Exelixis' return on equity.
Halozyme Therapeutics has a beta of 1.25, indicating that its share price is 25% more volatile than the S&P 500. Comparatively, Exelixis has a beta of 0.54, indicating that its share price is 46% less volatile than the S&P 500.
Summary
Halozyme Therapeutics beats Exelixis on 12 of the 17 factors compared between the two stocks.
Get Halozyme Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for HALO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HALO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Halozyme Therapeutics Competitors List
Related Companies and Tools
